Oryzon Genomics S.A. (ORYZF)
USD 3.03
(-0.66%)
USD 3.03
(-0.66%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -4.43 Million EUR | 16.02% |
| 2022 | -5.35 Million EUR | 22.82% |
| 2021 | -6.88 Million EUR | -58.08% |
| 2020 | -4.16 Million EUR | -14.17% |
| 2019 | -3.69 Million EUR | -32.11% |
| 2018 | -3.09 Million EUR | 23.58% |
| 2017 | -3.6 Million EUR | 2.15% |
| 2016 | -3.69 Million EUR | -535.44% |
| 2015 | 594.19 Thousand EUR | -93.11% |
| 2014 | 8.34 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.49 Million USD | -167.36% |
| 2024 Q2 | 3416.61 EUR | 128.21% |
| 2024 Q3 | -2.79 Million EUR | -428.52% |
| 2023 Q3 | -793.23 Thousand EUR | 32.62% |
| 2023 Q2 | -1.17 Million EUR | -5.06% |
| 2023 Q1 | -1.12 Million EUR | -111.22% |
| 2023 FY | - EUR | 16.02% |
| 2023 Q4 | -1.17 Million EUR | -47.67% |
| 2022 Q1 | -1.7 Million EUR | -129.1% |
| 2022 Q2 | 1.8 Million EUR | 206.15% |
| 2022 FY | - EUR | 22.82% |
| 2022 Q3 | -5.01 Million USD | -377.81% |
| 2022 Q4 | 9.98 Million EUR | 299.0% |
| 2021 Q2 | -1.53 Million EUR | 67.76% |
| 2021 FY | - EUR | -58.08% |
| 2021 Q3 | -4.35 Million USD | -183.85% |
| 2021 Q1 | -4.75 Million EUR | -386.7% |
| 2021 Q4 | 5.84 Million USD | 234.29% |
| 2020 Q2 | -1.15 Million EUR | -14.92% |
| 2020 FY | - EUR | -14.17% |
| 2020 Q4 | -977.99 Thousand EUR | 3.76% |
| 2020 Q3 | -1.01 Million EUR | 12.24% |
| 2020 Q1 | -1 Million EUR | -54.35% |
| 2019 Q2 | -1.29 Million EUR | -52.48% |
| 2019 Q1 | -852.05 Thousand EUR | -51.68% |
| 2019 Q4 | -652.84 Thousand EUR | 22.26% |
| 2019 FY | - EUR | -32.11% |
| 2019 Q3 | -839.73 Thousand EUR | 35.37% |
| 2018 FY | - EUR | 23.58% |
| 2018 Q2 | -792.26 Thousand EUR | -32.41% |
| 2018 Q3 | -809.54 Thousand EUR | -2.18% |
| 2018 Q4 | -561.74 Thousand EUR | 30.61% |
| 2018 Q1 | -598.31 Thousand EUR | 36.78% |
| 2017 Q4 | -946.39 Thousand EUR | -11.79% |
| 2017 Q2 | -1.05 Million EUR | -39.91% |
| 2017 Q1 | -756.94 Thousand EUR | 12.07% |
| 2017 FY | - EUR | 2.15% |
| 2017 Q3 | -846.56 Thousand EUR | 20.07% |
| 2016 Q2 | -1.37 Million EUR | -166.16% |
| 2016 FY | - EUR | -535.44% |
| 2016 Q1 | -518.26 Thousand EUR | -212.9% |
| 2016 Q4 | -860.83 Thousand EUR | -2.71% |
| 2016 Q3 | -838.12 Thousand EUR | 39.24% |
| 2015 Q3 | -78.36 Thousand EUR | -106.63% |
| 2015 Q4 | -165.63 Thousand EUR | -111.37% |
| 2015 FY | - EUR | -93.11% |
| 2015 Q1 | -306.04 Thousand EUR | 0.0% |
| 2015 Q2 | 1.18 Million EUR | 485.98% |
| 2014 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | -16.052% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 93.759% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1753.798% |
| SQZ Biotechnologies Company | -64.14 Million USD | 93.088% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -67.648% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 74.477% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 104.714% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -188.621% |
| Marizyme, Inc. | -34.28 Million USD | 87.068% |
| Genus plc | 73.7 Million USD | 106.015% |
| Pharming Group N.V. | 9.87 Million USD | 144.886% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -198.059% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -24.989% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 49.46% |
| ContraFect Corporation | -64.99 Million USD | 93.179% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -216.26% |
| IMV Inc. | -35.52 Million USD | 87.52% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -90.779% |
| ONE Bio Corp. | 13.61 Million USD | 132.567% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 90.807% |
| Mesoblast Limited | -62.38 Million USD | 92.894% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -755.785% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 224.114% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.218% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -601.03% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -94.063% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 25.225% |
| Biomind Labs Inc. | -1.03 Million USD | -328.53% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -53.28% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 38.093% |
| Skye Bioscience, Inc. | -13.54 Million USD | 67.276% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 66033.343% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 32.945% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -17633.432% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 2.051% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -14.135% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 72.064% |
| Accustem Sciences Inc. | -3.74 Million USD | -18.336% |
| EV Biologics, Inc. | -1.26 Million USD | -249.873% |
| Q BioMed Inc. | -617.62 Thousand USD | -617.804% |
| GB Sciences, Inc. | -1.41 Million USD | -212.234% |
| Alpha Cognition Inc. | -9.7 Million USD | 54.322% |
| CSL Limited | 4.78 Billion USD | 100.093% |
| Agentix Corp. | -1.37 Million USD | -223.189% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 88.815% |
| Enzolytics Inc. | -2.12 Million USD | -108.921% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -11.74 Million USD | 62.244% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -44.738% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -77.195% |
| argenx SE | -216.02 Million USD | 97.948% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 91.989% |
| HST Global, Inc. | -5303.00 USD | -83500.943% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 464.286% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -115.525% |
| Halberd Corporation | -74.27 Thousand USD | -5868.521% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 150.073% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1270.233% |
| Zenith Capital Corp. | -8.6 Million USD | 48.485% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -195.773% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -81.215% |
| AVAX Technologies, Inc. | -6.11 Million USD | 27.472% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -2418.605% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -130.795% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -25348.355% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | -328.428% |
| Helix BioMedix, Inc. | -1.04 Million USD | -323.713% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -153.335% |
| Kadimastem Ltd | -2.62 Million USD | -68.93% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 41.308% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -2348.179% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | 412.28 Thousand USD | 1175.319% |
| Cell Source, Inc. | -4.27 Million USD | -3.764% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -1107.272% |
| Regen BioPharma, Inc. | 1.46 Million USD | 402.421% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -373.17% |
| Affymax, Inc. | -14.29 Million USD | 68.987% |
| Mobile Lads Corp. | -2.24 Million USD | -97.815% |
| Itoco Inc. | -1.86 Million USD | -137.205% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1067.841% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -297.254% |
| International Stem Cell Corporation | 202 Thousand USD | 2294.732% |
| CytoDyn Inc. | -18.02 Million USD | 75.41% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -5509.786% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -36152.825% |
| Qrons Inc. | -40.08 Thousand USD | -10960.996% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -812.818% |
| SYBLEU INC | -141.57 Thousand USD | -3031.544% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 940.554% |
| Rebus Holdings, Inc. | -951 Thousand USD | -366.179% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -317.45% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -8322.033% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -80.076% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 87.64% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -9751.907% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -61.92% |
| Neutra Corp. | -181.24 Thousand USD | -2346.031% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 78.008% |
| PureTech Health plc | -11.62 Million USD | 61.87% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 78.007% |
| IXICO plc | -707 Thousand USD | -527.066% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 42.312% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 90.83% |
| CSL Limited | 4.73 Billion USD | 100.094% |
| Cellectis S.A. | -92.63 Million USD | 95.214% |